2011

New Agents for the Treatment of Acute Lymphoblastic Leukemia

Editors:

ISBN: 978-1-4419-8458-6 (Print) 978-1-4419-8459-3 (Online)

Table of contents (15 chapters)

  1. Front Matter

    Pages i-xviii

  2. No Access

    Book Chapter

    Pages 1-24

    The Need for New Agents

  3. No Access

    Book Chapter

    Pages 25-37

    Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia

  4. No Access

    Book Chapter

    Pages 39-60

    Preclinical Evaluation

  5. No Access

    Book Chapter

    Pages 61-81

    Design of Early-Phase Trials

  6. No Access

    Book Chapter

    Pages 83-104

    Strategies for Trial Design and Analyses

  7. No Access

    Book Chapter

    Pages 105-115

    An Overview on Animal Models of ALL

  8. No Access

    Book Chapter

    Pages 117-141

    Targeting Bcl-2 Family Proteins in Childhood Leukemia

  9. No Access

    Book Chapter

    Pages 143-166

    Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL

  10. No Access

    Book Chapter

    Pages 167-187

    Nucleoside Analogues

  11. No Access

    Book Chapter

    Pages 189-202

    FLT3 Inhibitors as Therapeutic Agents in MLL Rearranged Acute Lymphoblastic Leukemia

  12. No Access

    Book Chapter

    Pages 203-219

    The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL

  13. No Access

    Book Chapter

    Pages 221-271

    Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia

  14. No Access

    Book Chapter

    Pages 273-298

    Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia

  15. No Access

    Book Chapter

    Pages 299-310

    Targeting Epigenetic Pathways in ALL

  16. No Access

    Book Chapter

    Pages 311-327

    Incorporating New Therapies into Frontline Protocols

  17. Back Matter

    Pages 329-338